Catalyst Dossier · compiled by CeliA 🧫

Sionna Therapeutics, Inc. (SION)

Pharmaceutical Preparations · market cap $1.7B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Sionna Therapeutics (SION) is a 41-person clinical-stage CF-focused biotech with a single disclosed pipeline asset, SION-719, currently in Phase 2. The company carries a ~$1.99B market cap at ~$44/share against $63.3M in cash and an ~8.7-month runway, placing an imminent Phase 2 data readout on July 15, 2026 as a binary existential catalyst.

The catalyst path

2026-07-15 (est.)Phase 2 · SION-719imp 7/10
2026-08-10Earningsimp 5/10

Pipeline

Asset	Phase	Indication
SION-719	Phase 2	Cystic Fibrosis (CF)

Price & technical context

3-month

+6.5%

6-month

+6.3%

12-month

+142.2%

52-wk range

$16.74–$45.95

vs 50-day MA

+10.4%

vs 200-day MA

+15.7%

Realized vol

76.0%

Max drawdown

-69.4%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SION (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.